STUDY OBJECTIVES: To evaluate the effect of ramelteon on middle-of-the-night balance, mobility, and memory in older insomniacs. METHODS:Thirty-three older adults (age > or = 65 years) with insomnia were enrolled in a single-dose, 3-way crossover study of balance after bedtime administration of ramelteon, 8 mg; zolpidem, 10 mg (positive control); or placebo. Subjects were administered study medication 30 minutes before bedtime and were awakened 2 hours after dosing to evaluate balance (Sensory Organization Test), turning speed and stability, memory (immediate and delayed word recall), and adverse events. There was a 4- to 10-day washout between treatments. RESULTS:Ramelteon or zolpidem (positive control) was compared with placebo. There were no differences between placebo and ramelteon on the Sensory Organization Test (p = 0.837), turn time (p = 0.776), or turn sway (p = 0.982). The positive control (zolpidem) did reveal significant impairments on the Sensory Organization Test, turn time, and turn sway (p < 0.001, all). Immediate and delayed memory recall were not significantly different with ramelteon (p = 0.683 and p = 0.650, respectively). Immediate recall declined significantly with zolpidem (p = 0.002). Adverse events were infrequent (ramelteon, n = 7; placebo, n = 7; zolpidem, n = 13); none were serious. CONCLUSION: In older adults, ramelteon did not impair middle-of-the night balance, mobility, or memory relative to placebo.
RCT Entities:
STUDY OBJECTIVES: To evaluate the effect of ramelteon on middle-of-the-night balance, mobility, and memory in older insomniacs. METHODS: Thirty-three older adults (age > or = 65 years) with insomnia were enrolled in a single-dose, 3-way crossover study of balance after bedtime administration of ramelteon, 8 mg; zolpidem, 10 mg (positive control); or placebo. Subjects were administered study medication 30 minutes before bedtime and were awakened 2 hours after dosing to evaluate balance (Sensory Organization Test), turning speed and stability, memory (immediate and delayed word recall), and adverse events. There was a 4- to 10-day washout between treatments. RESULTS:Ramelteon or zolpidem (positive control) was compared with placebo. There were no differences between placebo and ramelteon on the Sensory Organization Test (p = 0.837), turn time (p = 0.776), or turn sway (p = 0.982). The positive control (zolpidem) did reveal significant impairments on the Sensory Organization Test, turn time, and turn sway (p < 0.001, all). Immediate and delayed memory recall were not significantly different with ramelteon (p = 0.683 and p = 0.650, respectively). Immediate recall declined significantly with zolpidem (p = 0.002). Adverse events were infrequent (ramelteon, n = 7; placebo, n = 7; zolpidem, n = 13); none were serious. CONCLUSION: In older adults, ramelteon did not impair middle-of-the night balance, mobility, or memory relative to placebo.
Authors: J Magaziner; W Hawkes; J R Hebel; S I Zimmerman; K M Fox; M Dolan; G Felsenthal; J Kenzora Journal: J Gerontol A Biol Sci Med Sci Date: 2000-09 Impact factor: 6.053
Authors: Carla R Schubert; Karen J Cruickshanks; Dayna S Dalton; Barbara E K Klein; Ronald Klein; David M Nondahl Journal: Sleep Date: 2002-12 Impact factor: 5.849
Authors: Anita K Wagner; Fang Zhang; Stephen B Soumerai; Alexander M Walker; Jerry H Gurwitz; Robert J Glynn; Dennis Ross-Degnan Journal: Arch Intern Med Date: 2004-07-26
Authors: Rachel E Fargason; Karen Gamble; Kristin T Avis; Rachel C Besing; Cherry W Jackson; Marshall E Cates; Roberta May Journal: Psychopharmacol Bull Date: 2011-05-15
Authors: Monique A J Mets; Juna M de Vries; Lieke M de Senerpont Domis; Edmund R Volkerts; Berend Olivier; Joris C Verster Journal: Sleep Date: 2011-10-01 Impact factor: 5.849
Authors: Thomas Roth; Patricia Berglund; Victoria Shahly; Alicia C Shillington; Judith J Stephenson; Ronald C Kessler Journal: J Clin Sleep Med Date: 2013-07-15 Impact factor: 4.062
Authors: Patricia Murphy; Margaret Moline; David Mayleben; Russell Rosenberg; Gary Zammit; Kate Pinner; Shobha Dhadda; Quan Hong; Luigi Giorgi; Andrew Satlin Journal: J Clin Sleep Med Date: 2017-11-15 Impact factor: 4.062